Health
Lilly Threatens Copycat Drug Makers After Zepbound Shortage
- Company is sending hundreds of cease-and-desist letters
- Shortage of Lilly’s Mounjaro, Zepbound ended last week
This article is for subscribers only.
Eli Lilly & Co. is ramping up its legal campaign against companies that were temporarily allowed to make and sell copycat versions of its blockbuster drugs used for weight loss until a US shortage ended last week.
The drugmaker said it’s sending hundreds of cease-and-desist letters Thursday to telehealth companies, compounding pharmacies and medical spas, demanding that they stop making, selling and promoting products that mimic Lilly’s Mounjaro and Zepbound.